EP0641193A4 - Combinaison de drogues chimiotherapeutiques. - Google Patents

Combinaison de drogues chimiotherapeutiques.

Info

Publication number
EP0641193A4
EP0641193A4 EP93914010A EP93914010A EP0641193A4 EP 0641193 A4 EP0641193 A4 EP 0641193A4 EP 93914010 A EP93914010 A EP 93914010A EP 93914010 A EP93914010 A EP 93914010A EP 0641193 A4 EP0641193 A4 EP 0641193A4
Authority
EP
European Patent Office
Prior art keywords
drug combinations
chemotherapeutic drug
chemotherapeutic
combinations
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93914010A
Other languages
German (de)
English (en)
Other versions
EP0641193A1 (fr
Inventor
Daniel S Martin
Robert L Stolfi
Joseph R Colofiore
L D Nord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Neuron Inc
Original Assignee
Daniel S Martin
Robert L Stolfi
Joseph R Colofiore
L D Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daniel S Martin, Robert L Stolfi, Joseph R Colofiore, L D Nord filed Critical Daniel S Martin
Publication of EP0641193A1 publication Critical patent/EP0641193A1/fr
Publication of EP0641193A4 publication Critical patent/EP0641193A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93914010A 1992-05-20 1993-05-20 Combinaison de drogues chimiotherapeutiques. Withdrawn EP0641193A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88580992A 1992-05-20 1992-05-20
US885809 1992-05-20
PCT/US1993/004775 WO1993023014A1 (fr) 1992-05-20 1993-05-20 Combinaison de drogues chimiotherapeutiques

Publications (2)

Publication Number Publication Date
EP0641193A1 EP0641193A1 (fr) 1995-03-08
EP0641193A4 true EP0641193A4 (fr) 1995-09-06

Family

ID=25387744

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93914010A Withdrawn EP0641193A4 (fr) 1992-05-20 1993-05-20 Combinaison de drogues chimiotherapeutiques.

Country Status (5)

Country Link
EP (1) EP0641193A4 (fr)
JP (1) JPH08506317A (fr)
AU (1) AU684709B2 (fr)
CA (1) CA2136091A1 (fr)
WO (1) WO1993023014A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US7381713B2 (en) 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
WO2002045720A1 (fr) * 2000-12-04 2002-06-13 Sloan-Kettering Institute For Cancer Research Traitement du cancer par reduction d'energie intracellulaire et a l'aide de pyrimidines
WO2004032947A1 (fr) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extrait ayant un action antitumoral et antitoxique
EP2711009A1 (fr) * 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Composés destinés à être utilisés dans le traitement ou la prévention du cancer primitif et métastatique du sein et de la prostate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55106517A (en) * 1979-02-08 1980-08-15 Daido Steel Co Ltd Convering of adsorption and deodorization vessel
JPS5637025A (en) * 1979-08-30 1981-04-10 Mitsubishi Electric Corp Deodorizing system
US5114951A (en) * 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MARTIN D S: "BIOCHEMICAL MODULATION PERSPECTIVES AND OBJECTIVES", HARRAP, K. R. AND T. A. CONNORS (ED.). BRISTOL-MYERS CANCER SYMPOSIA, VOL. 8. NEW AVENUES IN DEVELOPMENTAL CANCER CHEMOTHERAPY;8TH ANNUAL SYMPOSIUM ON CANCER RESEARCH, LONDON, ENGLAND, UK, SEPTEMBER 1985. XXXI+528P. ACADEMIC PRESS, INC.: ORLAN *
MARTIN D.S.: "Cancer Chemotherapy: Past is Prologue", MT. SINAI J. MED. (USA), 1985, 52, NO. 6, PAGE(S) 426-434 *
See also references of WO9323014A1 *

Also Published As

Publication number Publication date
AU4383493A (en) 1993-12-13
EP0641193A1 (fr) 1995-03-08
AU684709B2 (en) 1998-01-08
WO1993023014A1 (fr) 1993-11-25
CA2136091A1 (fr) 1993-11-25
JPH08506317A (ja) 1996-07-09

Similar Documents

Publication Publication Date Title
GR3025363T3 (en) Medicaments.
EP0670716A4 (fr) Substances pharmaceutiques au gout camoufle.
EP0597463A3 (en) Thermotherapiesonde.
EP0580285A3 (fr) Auto-réenclencheurs.
ZA934603B (en) thiazolylvinylphenyl derivatives.
GR1002074B (en) Rotomett granulation.
ZA927562B (en) Medicament.
EP0592130A3 (fr) Capsules dures.
EP0572808A3 (fr) Système de régulation antiblocage.
DE59204008D1 (en) Trachealstent.
ZA926482B (en) Cyanophenylpyrroles.
ZA927792B (en) Anti-alpha6-integrin-antibodies.
ZA939574B (en) Shaped charges.
EP0668864A4 (fr) Biphenylmethylimidazopyridines substituees.
ZA929294B (en) Syringe.
ZA929590B (en) Diphenylsulphides.
EP0599191A3 (fr) Circuit de régulation de vitesse d'un moteur.
EP0641193A4 (fr) Combinaison de drogues chimiotherapeutiques.
DE69205795D1 (en) Mesoprotheseunterlage.
EP0572573A4 (fr) Facteur de stimulation du chondrocyte derive de la thyroide.
EP0592354A3 (fr) Centrifugeuse à vide.
DE69203865D1 (en) Thermo-transferdrucksystem.
EP0663819A4 (fr) Association d'ibuprofene et de cafeine.
DE69204801D1 (en) Hydroxy- oder oxosubstituierte alkylcyclopentene.
EP0600754A3 (fr) Transfuseur pharmaceutique à débit continu.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IE IT LI NL

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PRO-NEURON, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NORD, L.D.

Inventor name: COLOFIORE, JOSEPH R.

Inventor name: STOLFI, ROBERT L.

Inventor name: MARTIN, DANIEL S.

RHK1 Main classification (correction)

Ipc: A61K 31/70

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IE IT LI NL

17Q First examination report despatched

Effective date: 19981208

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011203